Search

Your search keyword '"V. Di Martino"' showing total 369 results
Start Over Author "V. Di Martino"
369 results on '"V. Di Martino"'

1. Abstracts of the 33rd International Austrian Winter Symposium

Author

K. Binzel, A. Adelaja, C. L. Wright, D. Scharre, J. Zhang, M. V. Knopp, E. J. Teoh, D. Bottomley, A. Scarsbrook, H. Payne, A. Afaq, J. Bomanji, N. van As, S. Chua, P. Hoskin, A. Chambers, G. J. Cook, V. S. Warbey, A. Chau, P. Ward, M. P. Miller, D. J. Stevens, L. Wilson, F. V. Gleeson, K. Scheidhauer, C. Seidl, M. Autenrieth, F. Bruchertseifer, C. Apostolidis, F. Kurtz, T. Horn, C. Pfob, M. Schwaiger, J. Gschwend, C. D’Alessandria, A. Morgenstern, C. Uprimny, A. Kroiss, C. Decristoforo, E. von Guggenberg, B. Nilica, W. Horninger, I. Virgolini, S. Rasul, N. Poetsch, A. Woehrer, M. Preusser, M. Mitterhauser, W. Wadsak, G. Widhalm, M. Mischkulnig, M. Hacker, T. Traub-Weidinger, E. J. Wuthrick, E. D. Miller, P. Maniawski, Sebastijan Rep, Marko Hocevar, Janja Vaupotic, Urban Zdesar, Katja Zaletel, Luka Lezaic, S. Mairinger, Thomas Filip, M. Sauberer, S. Flunkert, T. Wanek, J. Stanek, N. Okamura, O. Langer, C. Kuntner, M. C. Fornito, R. Balzano, V. Di Martino, S. Cacciaguerra, G. Russo, D. Seifert, M. Kleinova, A. Cepa, J. Ralis, P. Hanc, O. Lebeda, M. Mosa, S. Vandenberghe, E. Mikhaylova, D. Borys, V. Viswanath, M. Stockhoff, N. Efthimiou, P. Caribe, R. Van Holen, J. S. Karp, P. M. Haller, C. Farhan, E. Piackova, B. Jäger, P. Knoll, A. Kiss, B. K. Podesser, J. Wojta, K. Huber, S. Mirzaei, A. Traxl, K. Komposch, Elisabeth Glitzner, M. Sibilia, M. Russello, S. Sorko, H. J. Gallowitsch, S. Kohlfuerst, S. Matschnig, M. Rieser, M. Sorschag, P. Lind, L. Ležaič, S. Rep, J. Žibert, N. Frelih, S. Šuštar, R. P. Baum, T. Langbein, A. Singh, M. Shahinfar, C. Schuchardt, G. F. Volk, H. R. Kulkarni, G. V. Di Martino, W. H. Thomson, M. Kudlacek, M. Karik, H. Rieger, W. Pokieser, K. Glaser, V. Petz, C. Tugendsam, W. Buchinger, B. Schmoll-Hauer, I. P. Schenk, K. Rudolph, M. Krebs, G. Zettinig, V. Zoufal, M. Krohn, T. Filip, J. Pahnke, F. Weitzer, B. Pernthaler, S. Salamon, R. Aigner, P. Koranda, L. Henzlová, M. Kamínek, Mo. Váchalová, P. Bachleda, D. Summer, J. Garousi, M. Oroujeni, B. Mitran, K. G. Andersson, A. Vorobyeva, J.n Löfblom, A. Orlova, V. Tolmachev, P. Kaeopookum, T. Orasch, B. Lechner, M. Petrik, Z. Novy, C. Rangger, and H. Haas

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920
Published
2018
Full Text
View/download PDF

2. Il tirocinio quale dispositivo per sostenere l’identità professionale degli educatori. Riflessioni su un percorso di tirocinio a distanza all’Università di Catania

Author

R. Piazza, V. Di Martino, Fiorucci, M, Zizioli, E, R. Piazza, and V. Di Martino

Subjects
tirocinio, formazione professionale, educatori
Abstract

L’irrompere della pandemia ha rappresentato una possibilità di rinnovamento per il mondo accademico. Con la chiusura improvvisa di tutte le attività in presenza, le Università hanno dovuto fare i conti con la necessità di salvaguardare i percorsi formativi degli studenti e delle studentesse. Soprattutto quelle istituzioni (la maggior parte in Italia), che non avevano mai affrontato il tema dell’erogazione a distanza delle attività didattiche, sono state costrette a fronteggiare la novità di un mondo dell’apprendimento “a distanza” (Piazza, 2020). Ovviamente anche l’Università di Catania si è trovata a fronteggiare questa situazione. Nello specifico, il Corso di laurea in Scienze dell’Educazione e della formazione (CdS L-19), risolto velocemente il problema dell’erogazione dei corsi, ha cercato delle soluzioni maggiormente calibrate sulle necessità degli studenti per favorire la loro esperienza di tirocinio, considerata un’attività formativa essenziale per costruire la propria identità professionale come educatore/educatrice. Il testo che segue racconta dell’esperienza realizzata e di come, da un’emergenza, sia scaturita una proposta formativa valida, mantenuta anche al ritorno delle attività in presenza.

Published
2022

5. Qualitative Objectives to Preserve, Protect and Valorise the Lombardy Rural Landscapes in the Regional Landscape Plan

Author

S. Restelli, V. di Martino, and Andrea Arcidiacono

Subjects
Rural landscape, European Landscape Convention, Landscape planning, business.industry, Abandonment (legal), Identity (social science), Peripheralization, Rural landscape, Landscape planning, Context (language use), Plan (drawing), Natural (archaeology), Variety (cybernetics), Geography, business, Environmental planning, Peripheralization
Abstract

Twenty years after the European Landscape Convention, the paper aims at reflecting on the role of landscape planning in contrasting peripheralization processes and risks in rural contexts. The issue is debated referring to the research studies developed in the frame of the ongoing review process of the Lombardy Regional Landscape Plan. The Lombardy context is considered as representative of a huge variety of landscape conditions, as well as the rural system is recognised as one of the main components structuring and defining the identity of the regional territory. The rural landscape is formed by the interaction between anthropic and natural elements that express the cultural and productive traditions characterising the different territorial contexts within the Region. At the same time, these rural contexts are potentially affected by several peripheralization risks due to abandonment, degradation, banalisation phenomena or land take and fragmentation processes. In this frame, the paper presents three main qualitative objectives defined to preserve, protect and valorise the different rural landscapes characterising the Lombardy Region context facing potential peripheralization risks.

Published
2021

7. Lithium treatment reverses irradiation-induced changes in rodent neural progenitors and rescues cognition

Author

Zanni, G. Goto, S. Fragopoulou, A.F. Gaudenzi, G. Naidoo, V. Di Martino, E. Levy, G. Dominguez, C.A. Dethlefsen, O. Cedazo-Minguez, A. Merino-Serrais, P. Stamatakis, A. Hermanson, O. Blomgren, K.

Abstract

Cranial radiotherapy in children has detrimental effects on cognition, mood, and social competence in young cancer survivors. Treatments harnessing hippocampal neurogenesis are currently of great relevance in this context. Lithium, a well-known mood stabilizer, has both neuroprotective, pro-neurogenic as well as antitumor effects, and in the current study we introduced lithium treatment 4 weeks after irradiation. Female mice received a single 4 Gy whole-brain radiation dose on postnatal day (PND) 21 and were randomized to 0.24% Li2CO3 chow or normal chow from PND 49 to 77. Hippocampal neurogenesis was assessed on PND 77, 91, and 105. We found that lithium treatment had a pro-proliferative effect on neural progenitors, but neuronal integration occurred only after it was discontinued. Also, the treatment ameliorated deficits in spatial learning and memory retention observed in irradiated mice. Gene expression profiling and DNA methylation analysis identified two novel factors related to the observed effects, Tppp, associated with microtubule stabilization, and GAD2/65, associated with neuronal signaling. Our results show that lithium treatment reverses irradiation-induced loss of hippocampal neurogenesis and cognitive impairment even when introduced long after the injury. We propose that lithium treatment should be intermittent in order to first make neural progenitors proliferate and then, upon discontinuation, allow them to differentiate. Our findings suggest that pharmacological treatment of cognitive so-called late effects in childhood cancer survivors is possible. © 2019, The Author(s).

Published
2021

8. AF.87 RESIST-HCV CRITERIA ARE ABLE TO RULE OUT ESOPHAGEAL VARICES PROGRESSION IN PATIENTS WITH HCV CIRRHOSIS TREATED BY DIRECT-ACTING ANTIVIRAL AGENTS(DAAS)

Author

M. Licata, Antonio Craxì, Y. Abdel Hadi, L. Crapanzano, V. Di Martino, S. Petta, L. Di Marco, V. Di Marco, C. Cammà, F. Simone, and Vincenza Calvaruso

Subjects
medicine.medical_specialty, Cirrhosis, Esophageal varices, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, In patient, medicine.disease, business, Direct acting
Published
2021
Full Text
View/download PDF

10. PNPLA3 rs738409 C >G variant is associated with a higher risk of liver fibrosis progression assessed by FIB-4 and stiffness by fibroscan in patients with non-alcoholic fatty liver disease

Author

S. Petta, Rosaria Maria Pipitone, Grazia Pennisi, Stefania Grimaudo, V. Di Marco, Antonio Craxì, Federica Spatola, C. Cammà, and V. Di Martino

Subjects
medicine.medical_specialty, Hepatology, business.industry, Liver fibrosis, Fatty liver, Gastroenterology, Non alcoholic, Disease, medicine.disease, Internal medicine, medicine, In patient, business
Published
2020
Full Text
View/download PDF

11. Etude randomisée évaluant deux procédures de jeûne (6 versus 2 heures) avant une endoscopie digestive haute chez des patients cirrhotiques (Etude GASTROPREP)

Author

C Emont, D. Cazaux, P Sage, Francine Fein, I. Tchoumak, A Chupin, G Claudé, Julienne Grillot, Claire Vanlemmens, Stéphane Koch, Thierry Thevenot, C Briot, C. Prothe, G Boivineau, C Biron, O Comiti, M. Stouvenot, J.-P. Cervoni, V. Di Martino, Lucine Vuitton, C D'engremont, and T Deregnaucourt

Published
2019
Full Text
View/download PDF

12. Impact of postoperative events on the occurrence of anastomotic biliary strictures after liver transplantation

Author

Alexandre Doussot, J. Magnin, B. Paquette, Célia Turco, Bruno Heyd, Marianne Latournerie, Anne Minello, C. Clerc, Claire Vanlemmens, P. Georges, Zaher Lakkis, and V. Di Martino

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Medicine, Anastomosis, Liver transplantation, business, Surgery
Published
2021
Full Text
View/download PDF

14. Évaluation non invasive de la fibrose hépatique chez des patients atteints de psoriasis, polyarthrite rhumatoïde ou maladie de Crohn traités par méthotrexate

Author

Thierry Thevenot, Paul Calès, Eric Toussirot, Daniel Wendling, R. Blondet, V. Di Martino, J.-P. Cervoni, P. Zhong, B. Alby-Lepresle, François Aubin, Elisabeth Monnet, Delphine Weil, and Franck Carbonnel

Subjects
Dermatology
Abstract

Introduction L’hepatotoxicite rapportee avec le methotrexate souligne la necessite d’une evaluation repetee, non invasive et fiable de la fibrose hepatique. Nous avons depiste, par une strategie non invasive chez des patients traites par methotrexate, la prevalence et les facteurs predictifs d’une fibrose hepatique significative (fibrose ≥ F2). Materiel et methodes La fibrose a ete depistee prospectivement en utilisant 9 tests non invasifs chez des patients consecutifs atteints de psoriasis, de polyarthrite rhumatoide ou de maladie de Crohn. La fibrose significative a ete evaluee sans biopsie hepatique en definissant une « methode specifique » (resultat donne par la majorite des tests) et une « methode sensible » (au moins un test indiquant un stade ≥ F2). Resultats Un total de 131 patients (66 psoriasis, 40 polyarthrite rhumatoide et 25 maladie de Crohn) ont ete recrutes, dont 83 recevaient du methotrexate. Sept tests ont ete realises en moyenne par patient, avec une concordance complete dans 75 % des cas. Le Fibroscan® etait interpretable chez seulement 61 % des patients. Les meilleures performances (AUROC > 0,9) pour predire une fibrose significative ont ete obtenues par des tests dedies a la steatohepatite (FibroMeter NAFLD, NFS et FPI). La prevalence de la fibrose ≥ F2 selon la methode « specifique » ou « sensible » de la fibrose etait respectivement de 10 % et 28 %. L’exposition au methotrexate n’influencait pas le stade de la fibrose. Selon notre « methode sensible », les facteurs independamment associes a une fibrose significative etaient l’âge, le sexe masculin et le syndrome metabolique. Discussion Nous avons donc defini chez les patients traites par methotrexate, une approche non invasive pour identifier la fibrose hepatique significative (≥ F2) en utilisant 8 tests biochimiques et le Fibroscan®. Dans cette population, le risque de fibrose importante etait lie a l’âge, au sexe masculin et a la presence d’un syndrome metabolique, mais n’etait pas influence par le methotrexate.

Published
2020
Full Text
View/download PDF

16. Promotion of the mediterranean diet incancer long-survivors by means of the Med-Food Anticancer Program: a pilot study

Author

M, Panunzio, R, Caporizzi, E P, Cela, A, Antoniciello, V, Di Martino, and L R, Ferguson

Subjects
Adult, Male, Cancer Survivors, Italy, Neoplasms, Humans, Female, Pilot Projects, Health Promotion, Middle Aged, Diet, Mediterranean, Aged, Follow-Up Studies
Abstract

The intervention "Med-Anticancer Food Program" has proven to be effective in promoting the Mediterranean Diet, significantly increasing the Mediterranean Adequacy Index in healthy subjects. There are no studies that have investigated the effectiveness of this intervention in individuals who have had a diagnosis of cancer.To perform a pilot study to assess the opportunity of employing the methodology of the Med-Anticancer Food Program in order to encourage "long-term cancer survivors" to adhere to the Mediterranean Diet, as well as healthy people, and this in order to apply the program to larger groups.From the residents' register of Foggia, a city in southern Italy, forty adults of both sexes, over 25 years of age, were recruited at random and assigned (1:1) as follows: - Twenty healthy subjects to the intervention-1 group - Twenty long-term cancer survivors to the intervention-2 group. The Med-Anticancer Food Program was applied to both groups with an articulated intervention 11 weeks long, followed by a 52-week period of follow up. By means of a food diary of the last 3 days, the Mediterranean Adequacy Index values were calculated before intervention (T0), after a period of 11 weeks of interventions (T1) and at the end of the 52 weeks of follow-up period (T2). The H0 hypothesis of the study was that there are no differences between the two interventions in reaching by T1, and maintaining at T2, values of Mediterranean Adequacy Index around 7, considered the optimum for adherence to the Mediterranean diet.Out of the subjects assigned to the intervention-1 group (n = 20), 11 subjects have completed the 52-months follow-up (55.0% ); for intervention-2, 16 (80%) out of 20 have completed it. The average age of subjects was 52.1 years. The Mediterranean Adequacy Index, of intervention-1 group significantly increased from 2.8 (T0) to 9.2 (T1) and to 9.0 (T2) (p0.0001); whereas, in the intervention-2 group, Mediterranean Adequacy Index moved from 2.4 (T0) to 10.2 (T1) and to 9.3 (T2) (p0.0001). The difference of Mediterranean Adequacy Index between the two study groups at T1 and T2 was not significant. Such non-significance persists also after the stratification by sex and age obtained with Mantel-Haenszel procedure. The performance of the values of the laboratory parameters considered (folic acid, total cholesterol, alkyl resorcinol) was similar in the subjects of both intervention 1 and 2, without any difference, while considered at a basal level T0, at T1 and at the end of the follow-up period (T2).The results of our work suggest the feasibility of conducting the Med-Anticancer Food Program in long-term cancer survivors. The results of the pilot study show that such intervention, carried on a small number of long term cancer survivors, is adequate to assess its feasibility but, due to the limited size of our study, a confirmation is required through larger nutritional prevention intervention studies.

Published
2018

17. AB0438 Safety of tnf blockers in case of non-alcoholic fatty liver disease and cirrhosisa systematic review

Author

Delphine Weil-Verhoeven, Thierry Thevenot, V. Di Martino, Clément Prati, Frank Verhoeven, and Daniel Wendling

Subjects
Hepatitis, medicine.medical_specialty, Cirrhosis, business.industry, Autoimmune hepatitis, Hepatitis B, medicine.disease, Gastroenterology, Infliximab, Etanercept, Internal medicine, medicine, Adalimumab, Liver function, business, medicine.drug
Abstract

Background The management of inflammatory rheumatisms and psoriasis has largely evolved over the last 15 years with the emergence of biotherapies whose main adverse effect is the increased infection risk. The prevalence of metabolic syndrome is increasing and has been estimated at 30% in patients with rheumatoid arthritis with an excess of 45% compared to healthy subjects. One of the major complications of the metabolic syndrome is the Non Alcoholic Fatty Liver Disease (NAFLD), which prevalence is 25% in the global population, and 30% in a cohort of patients with rheumatoid arthritis. The main complication of NAFLD is the development of cirrhosis, known to increase infectious risk. Surprisingly, there are no data on the safety of TNF antagonists in patients with chronic inflammatory disease and NAFLD or cirrhosis. Objectives To assess infectious and liver safety of the main TNF blockers used in chronic inflammatory diseases in patients with cirrhosis or NAFLD. Methods A systematic review of the literature, following the Prisma recommendations, was conducted on the Pubmed and Embase databases with the following keywords: ”adalimumab”, ”infliximab”, ”etanercept”, ”certolizumab”, ”golimumab” ”TNF -blockers “AND” liver cirrhosis ”,” non alcoholic fatty liver disease “. We selected only studies including patients treated with TNF blockers and with cirrhosis or ultrasonically characterised NAFLD. We excluded animal models and non-English articles. Results We identified 39 articles and only 11 fulfilled the inclusion criteria. 9 Case Reports have reported the tolerance of TNF-blockers in patients with cirrhosis and one controlled study (44 patients) assessed the safety of etanercept in case of NAFLD. One study (7 patients) investigated the impact of infliximab in refractory autoimmune hepatitis. The cause of cirrhosis was primary biliary cholangitis (5 cases), alpha1 antitrypsin deficiency (4 cases) and post hepatitis B cirrhosis (2 cases). All cirrhosis were compensated. Inflammatory diseases requiring the introduction of TNF blocker were rheumatoid arthritis (n=5), psoriatic arthritis (n=4), ulcerative colitis (n=2) and psoriasis (n=44). The TNF-blockers prescribed were adalimumab in 2 patients, infliximab in 11 patients and etanercept in 49 patients. The duration of treatment ranged from 6 to 24 months. For the 9 cirrhotic patients with an inflammatory disorder, no infection was reported and two of them (2 cases of primary biliary cholangitis) even had an improvement in liver function secondary to the introduction of biotherapy. For the 7 patients receiving infliximab to treat auto-immune hepatitis, 5 patients presented recurrent infections. For patients with NAFLD, no infectious event was reported and an improvement of the hepatic biological parameters was observed, suggesting an improvement in liver function. Conclusions The results of this review suggest that in case of compensated cirrhosis, TNF-blockers were not deleterious for the liver and did not increase the infectious risk. In case of auto-immune cirrhosis, TNF-blockers increased the infectious risk. In case of NAFLD, TNF-blockers might improve liver function and prevent fibrosis. Disclosure of Interest None declared

Published
2018
Full Text
View/download PDF

18. Safety of sofosbuvir-based regimens after liver transplantation longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

Author

Rodolphe Anty, Alpha Diallo, Vincent Leroy, L. D’Alteroche, Jean Charles Duclos-Vallée, Claire Fougerou-Leurent, Christophe Duvoux, Vincent L.M. Esnault, P. Perré, François Habersetzer, Audrey Coilly, Aurelie Veislinger, Nassim Kamar, V. Di Martino, Emilie Rossignol, Valérie Canva, Maryline Debette-Gratien, Carole Cagnot, François Durand, Didier Samuel, Clémence M. Canivet, Danielle Botta-Fridlund, H. Montialoux, V. de Ledinghen, Christine Silvain, Camille Besch, Jérôme Dumortier, Albert Tran, Guillaume Favre, Pauline Houssel-Debry, Georges Philippe Pageaux, S. Radenne, H. Danjou, Sébastien Dharancy, Fabio Conti, Pascal Lebray, Armando Abergel, Christophe Moreno, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Laboratoire de PhysioMédecine Moléculaire (LP2M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Toulouse [Toulouse], Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Edouard Herriot [CHU - HCL], Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Strasbourg, CHU Marseille, CHU Rouen, Normandie Université (NU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, CHU Limoges, ANRS France Recherche Nord & sud Sida-hiv hépatites, Hôpital Lapeyronie [Montpellier] (CHU), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
medicine.medical_specialty, Sofosbuvir, Hepatitis C virus, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Urology, Renal function, Hepacivirus, 030230 surgery, Liver transplantation, medicine.disease_cause, Kidney, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Ribavirin, Medicine, Humans, Pharmacology (medical), Longitudinal Studies, Prospective Studies, Renal Insufficiency, Chronic, Aged, Creatinine, Hepatology, business.industry, Gastroenterology, Middle Aged, Hepatitis C, 3. Good health, Liver Transplantation, medicine.anatomical_structure, chemistry, Cohort, 030211 gastroenterology & hepatology, Female, business, medicine.drug, Glomerular Filtration Rate
Abstract

International audience; Background In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir-based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. Aim To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. Methods In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. Slopes of eGFR were defined as a change in eGFR during a period divided by time. Pre-treatment, on-treatment and post-treatment periods were 9 months, 3-9 months and 4.5 months. Interactions between eGFR slopes and the pre-treatment eGFR, use of ribavirin or mycophenolate mofetil, and stage of fibrosis were addressed. On-treatment eGFR slopes were separated in tertiles. Pre- and post-treatment eGFR slopes were compared globally and according to tertiles. Results The post-treatment eGFR slope was significantly better than pre-treatment eGFR slope (+0.18 (IQR -0.76 to +1.32) vs -0.11 (IQR -1.01 to +0.73) mL/min/1.73 m(2)/month, P=0.03) independently of the pre-treatment eGFR (P=0.99), ribavirin administration (P=0.26), mycophenolate mofetil administration (P=0.51) and stage of fibrosis (F3 and F4 vs lower stages, P=0.18; F4 vs lower stages, P=0.08; F4 Child-Pugh B and C vs lower stages, P=0.38). Tertiles of on-treatment eGFR slopes were -1.71 (IQR -2.54 to -1.48), -0.78 (IQR -1.03 to -0.36) and +0.75 (IQR +0.28 to +1.47) mL/min/1.73 m(2)/month. Pre- and post-treatment eGFR slopes were not significantly different according to tertiles (respectively, P=0.34, 0.08, 0.73). Conclusion The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir-based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients.

Published
2018
Full Text
View/download PDF

19. 'Five-A-Day' and the Med-Food Anticancer Program

Author

V, Piazzolla, M F, Panunzio, R, Caporizzi, E P, Cela, V, Di Martino, A, Antoniciello, R, Prato, C A, Germinario, D, Lagravinese, M, Conversano, and L R, Ferguson

Subjects
Italy, Neoplasms, Humans, Diet, Healthy
Published
2017

20. Impact of Cytomegalovirus infection on the outcome of patients with cirrhosis: a preliminary study

Author

Jean-Baptiste Bour, Laurent Andreoletti, Vanessa Cottet, Jean-Louis Jouve, J.-J. Raabe, Elisabeth Monnet, Gérard Thiéfin, Samira Fafi-Kremer, Morgan Faivre, Séverine Valmary-Degano, Georges Herbein, François Habersetzer, Michel Doffoel, Brice Malve, Hélène Barraud, V. Di Martino, Evelyne Schvoerer, Jean-Pierre Bronowicki, Christine Binquet, C. Richou, Patrick Hillon, Service d'Hépatologie, Hôpital Jean Minjoz, Centre Hospitalier Universitaire de Besançon, Université de Franche Comté, Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz [Besançon], Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques ( CIC-EC ), Université de Bourgogne ( UB ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Unité de virologie médicale [Reims], Hôpital Robert Debré, Service d'Hépato-gastro-entérologie [CHR Metz-Thionville], Centre hospitalier régional Metz-Thionville ( CHR Metz-Thionville ), Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Laboratoire de Virologie [Strasbourg], Service d'Ophtalmologie (CHU de Dijon), Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie ( CIC-P803 ), Université de Bourgogne ( UB ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Service d'hépato-gastroentérologie, CHU Strasbourg-Hopital Civil, Centre d'Investigation Clinique de Besançon ( CICB ), Etablissement Français du Sang Bourgogne Franche-Comté-Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Franche-Comté ( UFC ), Service d'hépatogastroentérologie (CHU Reims), Centre Hospitalier Universitaire de Reims ( CHU Reims ), Service d'Hépatologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'Anatomie pathologique [CHRU Besançon], Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie (CIC-P803), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction Générale de l'Organisation des Soins (DGOS)-Université de Bourgogne (UB), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])

Subjects
Clinical aspects, Cirrhosis and its complications, 0303 health sciences, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Clinical aspects, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Gastroenterology, Outcome (game theory), 3. Good health, Cytomegalovirus infection, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, 030211 gastroenterology & hepatology, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Cirrhosis and its complications, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology
Abstract

International audience

Published
2017
Full Text
View/download PDF

21. OC-0067 Continuous Positive Airway Pressure (CPAP): an innovative respiratory gating in lymphoma patients

Author

G. Furfaro, Riccardo Ragona, L. Focaraccio, V. Di Martino, C. Cavallin, P. Solidoro, Giuseppe Carlo Iorio, Mario Levis, V. De Luca, Carmela Palladino, Sara Bartoncini, Francesca Romana Giglioli, Umberto Ricardi, E. Gallio, R. Parise, G. Rovere, and A. Mattei

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Respiratory gating, Hematology, medicine.disease, Lymphoma, Oncology, Internal medicine, medicine, Cardiology, Radiology, Nuclear Medicine and imaging, Continuous positive airway pressure, business
Published
2019
Full Text
View/download PDF

22. Impact pronostique de la concentration de 3-hydroxymyristate sur la survie des patients atteints de cirrhose alcoolique ou virale

Author

G. Thieffin, C. Richou, Jean Faivre, David Masson, L. Granconato, Patrick Hillon, Vanessa Cottet, G.D. Sockalingum, Brigitte Bernard-Chabert, Jean-Pierre Bronowicki, P. Trechot, M. Tebacher-Alt, P. Oudet, Christine Binquet, Laurence Duvillard, M.-B. Valnet-Rabier, Michel Doffoel, J.-P. Pais de Barros, Jean-Louis Jouve, M. Manfait, Thomas Mouillot, Anne Minello, Marianne Latournerie, Jean-Michel Petit, D. Vuitton, Catherine Sgro, François Habersetzer, Dominique Delmas, Laurent Lagrost, V. Di Martino, T. Trenque, Jean-Louis Guéant, and Valérie Jooste

Subjects
Epidemiology, Public Health, Environmental and Occupational Health
Abstract

Etat de la question Le role de l’endotoxemie liee a la translocation bacterienne sur l’aggravation de la cirrhose fait l’objet de nombreuses etudes, mais son impact sur la mortalite au cours de la cirrhose est mal connu. Le but de ce travail etait d’etudier l’impact de la concentration sanguine de 3-hydroxymyristate (3-HM) total (composant specifique des lipopolysaccharides, endotoxine), sur le risque de deces et de complications des malades cirrhotiques. Materiel et methodes Au total, 593 patients atteints de cirrhose alcoolique ou virale, sans carcinome hepatocellulaire ont ete inclus entre 2008 et 2012 dans six centres hospitalo-universitaires francais. Le dosage de 3-HM total, libre et lie aux lipoproteines a ete realise en l’absence de complication aigue de la cirrhose par une methode innovante et brevetee de dosage massique des LPS. Le suivi annuel pendant cinq ans a permis de relever la survenue de complications ou du deces. L’analyse de survie a ete realisee par un modele de Cox multivarie avec stratification sur le centre et la severite de la cirrhose. Resultats Les patients avec une concentration de 3-HM elevee avait une cirrhose plus severe que les autres selon les scores de Child-Pugh et de Meld (p Conclusion Une concentration elevee de 3-HM, marqueur specifique de l’endotoxemie, est associee a un sur-risque de deces a cinq ans chez les patients avec cirrhose alcoolique ou virale compensee (Child Pugh A) suggerant un role majeur de la translocation bacterienne dans l’aggravation de la cirrhose.

Published
2019
Full Text
View/download PDF

23. Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study

Author

Jean Charles Duclos-Vallée, F. Durand, Valérie Canva, V. Di Martino, Abou Diallo, G.-P. Pageaux, S. Radenne, Claire Fougerou-Leurent, Emilie Rossignol, Aurelie Veislinger, Pauline Houssel-Debry, Rodolphe Anty, H. Danjou, Vincent Leroy, Christophe Duvoux, L. D’Alteroche, C. Silvain, Audrey Coilly, V. de Ledinghen, Camille Besch, Caroline Jezequel, Maryline Debette-Gratien, A. Rohel, François Habersetzer, Nassim Kamar, H. Montialoux, Jérôme Dumortier, Armando Abergel, Christophe Moreno, Fabio Conti, Pascal Lebray, Danielle Botta-Fridlund, P. Perré, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Service d'Hépatologie, Hôpital Henri Mondor, AP-HP, Créteil, France., Hôpital Henri Mondor, Hôpital Paul Brousse, Département d'hépatologie, Hospices Civils de Lyon (HCL), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Services de Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille, CHU Pitié-Salpêtrière [AP-HP], Service d'hépato-gastroentérologie, Hôpital de la Conception, AP-HM, Marseille, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire Inflammation, Tissus épithéliaux et Cytokines (LITEC), Université de Poitiers, Service de Transplantation, Centre Hospitalier Universitaire de Strasbourg, Centre Hospitalier Universitaire de Strasbourg (CHU de Strasbourg ), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Unité de la recherche fondamentale et clinique sur l' hépatite virale, France Recherche Nord & Sud Asdi-VIH Hépatites, Agence Nationale de Recherche sur le Sida, Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Ribavirin, [SDV]Life Sciences [q-bio], Hepatitis C, 030230 surgery, Liver transplantation, medicine.disease, Gastroenterology, 3. Good health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Internal medicine, Medicine, 030211 gastroenterology & hepatology, business
Abstract

International audience; EASL International Liver Congress, APR 13-17, 2016, Barcelona, SPAIN

Published
2016
Full Text
View/download PDF

24. Daclatasvir plus Sofosbuvir with or without Ribavirin in Patients with HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate use Programme

Author

V. Di Martino, Frédéric Oberti, G.-P. Pageaux, D. Blaison, Fabio Conti, Eric Nguyen-Khac, D. Lacoste, Ghassan Riachi, Vincent Leroy, Christophe Hézode, Raoudha Akremi, Mariagrazia Tateo, Yacia Bennai, S. Metivier, Jean-Pierre Bronowicki, Dominique Guyader, J. Vergniol, C. Michau, Hélène Fontaine, Régine Truchi, Anne Filipovics, Epidémiologie pronostique des cancers et affections graves, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Comité de coordination Régionale de lutte contre l'infection due au Virus de l'immunodéficience Humaine, Partenaires INRAE, Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Nice (CHU Nice), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre hospitalier de Saint-Nazaire, Centre hospitalier Troyes (CH Troyes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Bristol-Myers Squibb Company, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Hôpital Charles Nicolle [Rouen]-CHU Rouen

Subjects
medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, Ribavirin, [SDV]Life Sciences [q-bio], Compassionate Use, Interim analysis, Decompensated cirrhosis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, In patient, business, medicine.drug
Abstract

EASL International Liver Congress, Barcelona, SPAIN, APR 13-17, 2016; International audience

Published
2016
Full Text
View/download PDF

25. Long‐term outcome of chronic hepatitis C in a population‐based cohort and impact of antiviral therapy: a propensity‐adjusted analysis

Author

Patrick Hillon, Thierry Thevenot, V. Di Martino, J. Crouzet, Elisabeth Monnet, and Anne Minello

Subjects
Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Multivariate analysis, Cirrhosis, Adolescent, Alcohol Drinking, Population, Antiviral Agents, Gastroenterology, Polyethylene Glycols, Cohort Studies, Virology, Internal medicine, Ribavirin, medicine, Humans, education, Aged, education.field_of_study, Hepatology, business.industry, Liver Neoplasms, Interferon-alpha, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Recombinant Proteins, Surgery, Treatment Outcome, Infectious Diseases, Hepatocellular carcinoma, Propensity score matching, Female, Liver cancer, business, Cohort study
Abstract

This population-based study aimed to assess thedeterminants of the outcome of chronic hepatitis C withanalysis of the impact of antiviral therapy with or withoutsustained virological response (SVR) on cirrhosis decom-pensation, hepatocellular carcinoma, liver-related and non-liver-related mortality. A total of 1159 HCV-positive patientsnewly detected between 1994 and 2001 were included. Foreach outcome, the prognostic effect of patients baselinecharacteristics was estimated by time-dependent Cox modelsusing age as the time-scale and adjusting for treatmentreceived during follow-up. The impact of antiviral therapywas assessed by using a propensity score in a sampleincluding 184 patients treated in the first 24 months fol-lowing diagnosis who were matched to 184 untreatedpatients. At the end of a 59-month median follow-up, 100cases of compensated disease, 58 liver cancer and 163deaths (55 liver related) were recorded. The 5-year rates ofdecompensated cirrhosis, hepatocellular carcinoma, liver-related and non-liver-related death were 4.4%, 2.7%, 5.0%and 8.9%, respectively. Multivariate analyses identified twovariables with pejorative influence: alcohol consumption(RR = 4.29 for CD; RR = 5.76 for HCC; RR = 6.69 for liver-related death; P < 0.0001); HCV diagnosis unrelated tosystematic screening (RR = 2.25 for CD; RR = 3.05 forHCC; RR = 4.31 for liver-related death, P < 0.03). In thematched subset, no significant benefit of antiviral therapywas observed. Nevertheless, among the 144 patients whoachieved SVR, no death was observed. This population-basedstudy showed substantial rates of decompensated cirrhosis,hepatocellular carcinoma and non-liver-related mortality.Alcohol consumption and absence of systematic screeningwere significant determinants of poor outcome, whereastreatment did not have significant influence.Keywords: antiviral therapy, hepatitis C, liver-related mor-tality, non-liver-related mortality, outcome, population-based cohort study, survival bias.

Published
2011
Full Text
View/download PDF

26. Facteurs nutritionnels et risque de carcinome hépatocellulaire chez des personnes atteintes de cirrhose

Author

Michel Doffoel, Patrick Hillon, Vanessa Cottet, V. Di Martino, Melissa Rizk, Jean-Pierre Bronowicki, A. Guilloteau, M. Diab Assaf, A. Busson, G. Thiefin, and Thomas Mouillot

Subjects
Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract

Introduction et but de l’etude Le carcinome hepatocellulaire (CHC) se developpe dans 80 % des cas sur un foie cirrhotique. En France, l’incidence augmente et les traitements restent peu efficaces. L’alimentation peut etre un moyen de prevention interessant mais les resultats d’etudes dans ce domaine restent rares et divergents. Notre objectif etait donc d’etudier les liens entre differents facteurs alimentaires et le risque de CHC dans une population francaise atteinte de cirrhose. Materiel et methodes Pour l’etude multicentrique Cirrhose et risque de carcinome hepatocellulaire dans le grand est (CiRCE), des patients cirrhotiques avec CHC histologiquement confirme (cas) et des patients cirrhotiques sans CHC a l’inclusion (temoins) ont ete recrutes entre 2008 et 2012 dans 6 hopitaux de l’Est de la France. Les consommations (g/j) de 208 aliments et 22 nutriments etaient obtenus a l’aide d’un questionnaire type histoire alimentaire et sa table de composition. La methode des residus et un decoupage en tertiles etaient ensuite utilises. Les Odds Ratio (OR) et leurs intervalles de confiance (CI) a 95 % etaient obtenus par regression logistique multivariee. Resultats et analyse statistique Les 181 cas avec CHC inclus etaient plus âges (64,4 ans vs 59 ans, p Conclusion Nos resultats preliminaires mettent en evidence des relations interessantes entre des facteurs alimentaires et le risque de CHC chez des patients atteints de cirrhose. L’analyse des profils de consommations alimentaires selon l’etiologie de la cirrhose et les liens avec certains parametres biologiques sont en cours. Nos resultats devront etre confirmes dans de plus larges etudes.

Published
2018
Full Text
View/download PDF

27. P.09.17 PNPLA3 RS738409 POLYMORPHISM PREDICTS THE DEVELOPMENT AND THE SEVERITY OF HEPATIC STEATOSIS, BUT NOT METABOLIC SYNDROME, IN PATIENTS WITH CELIAC DISEASE

Author

Anna Alisi, Antonio Rispo, N. Gerbino, Valerio Nobili, Filomena Morisco, Luca Miele, Annalisa Crudele, Nicola Imperatore, Francesca Ferretti, V. Di Martino, R. Tortora, and Nicola Caporaso

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, In patient, Disease, Steatosis, Metabolic syndrome, medicine.disease, business
Published
2018
Full Text
View/download PDF

28. Le syndrome hépatopulmonaire

Author

Eric Nguyen-Khac, J-P Cervoni, Jean François Cadranel, Claire Vanlemmens, C. Richou, Thierry Thevenot, G. Mantion, Catherine M. Pastor, Christian Jacquelinet, V. Di Martino, and Bruno Heyd

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, 030228 respiratory system, business.industry, Gastroenterology, Medicine, 030211 gastroenterology & hepatology, General Medicine, business, 3. Good health
Abstract

Resume Le syndrome hepatopulmonaire est caracterise par une hypertension portale avec ou sans cirrhose, une augmentation du gradient alveolo-arteriel en oxygene en air ambiant superieure ou egale a 15 mmHg, et des dilatations vasculaires intrapulmonaires au niveau des vaisseaux capillaires. Chez les malades cirrhotiques, la prevalence du syndrome hepatopulmonaire est estimee a 20 %. Le diagnostic est fait par l’echographie cardiaque de contraste. La physiopathologie du syndrome hepatopulmonaire ferait intervenir essentiellement une augmentation de la production pulmonaire de monoxyde d’azote. L’hypoxemie s’aggrave progressivement et augmente la mortalite. Une surveillance rapprochee des patients hypoxemiques est necessaire pour envisager une transplantation hepatique dans des conditions optimales. En effet, les principaux facteurs de mortalite postgreffe sont une PaO2 inferieure ou egale a 50 mmHg seule ou associee a un shunt isotopique superieur a 20 %. Nombreux sont les medicaments qui ont ete testes dans le syndrome hepatopulmonaire, mais les resultats probants sont rares : la poudre d’ail et, plus recemment, les aerosols d’iloprost pourraient ameliorer de facon prolongee l’oxygenation des patients avant et apres la transplantation hepatique.

Published
2009
Full Text
View/download PDF

29. L’hepar lobatum carcinomatosum : une cause rare d’hypertension portale compliquant les métastases hépatiques d’un carcinome mammaire

Author

J.-P. Cervoni, N. Sailley, V. Di Martino, C. Richou, A. Dobrin, Thierry Thevenot, L. Chaigneau, and Claire Vanlemmens

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Gastroenterology, Medicine, 030211 gastroenterology & hepatology, General Medicine, business
Abstract

Resume L’hepar lobatum carcinomatosum correspond a une dysmorphie hepatique majeure non cirrhotique acquise au cours de l’evolution d’un carcinome, le plus souvent d’origine mammaire, metastase au foie. Il s’associe souvent a une hypertension portale. Il est la consequence d’un envahissement des veinules portes par les cellules tumorales et d’une reaction desmoplastique au contact de la tumeur. Le pronostic est sombre en depit d’une impression de regression tumorale en imagerie. Nous rapportons un cas d’hepar lobatum carcinomatosum revele par une rupture de varices œsophagiennes. Le diagnostic a pu etre documente par les donnees de l’imagerie par resonance magnetique dans un contexte clinique evocateur.

Published
2008
Full Text
View/download PDF

30. Coeliac disease in chronic hepatitis C: a French multicentre prospective study

Author

Christophe Renou, Jean François Cadranel, Patrice Dumouchel, Thierry Thevenot, N. Abdelli, Elisabeth Monnet, Vincent Jouannaud, Eric Nguyen-Khac, Solange Bresson-Hadni, Jacques Denis, H. Labadie, V. Di Martino, and M. Chousterman

Subjects
medicine.medical_specialty, Cirrhosis, Hepatitis C virus, Population, Context (language use), medicine.disease_cause, Gastroenterology, Coeliac disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Immunopathology, medicine, Pharmacology (medical), 030212 general & internal medicine, education, Prospective cohort study, education.field_of_study, Hepatology, business.industry, medicine.disease, 3. Good health, 030211 gastroenterology & hepatology, Viral disease, business
Abstract

Summary Background A prevalence of 1.2% of coeliac disease (CD) in patients with chronic hepatitis C was recently reported, suggesting a possible epidemiological link between these two diseases. However, other studies have not found this relationship. Aim To conduct a French multicentre prospective study to assess the prevalence of CD in hepatitis C virus (HCV)-infected patients. Methods Between June 2003 and November 2005, 624 consecutive HCV-positive out-patients were tested for antiendomysial IgA antibodies (AEA), antigliadin IgA and IgG antibodies (AGA). Patients with positive AEA or IgA AGA and positive IgG AGA in a context of a high suspicion of CD were asked to undergo gastroscopy with duodenal biopsies. Results Isolated IgA AEA, IgA AGA and IgG AGA were 0.16%, 5.7% and 4.4%, respectively. Gastroscopy was required for 39 patients, 31 were performed (eight refusals), but only 25 duodenal biopsies were performed as six patients had cirrhosis. CD was never detected. Conclusions The prevalence of CD in HCV-positive patients was 0% (95% confidence interval: 0–0.59%), but there is a low prevalence of CD in the whole French population.

Published
2007
Full Text
View/download PDF

31. Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study

Author

V. Di Martino, Thierry Poynard, M. Simon-Rudler, J. Massard, Dominique Thabut, V. Ratziu, and Brigitte Bernard-Chabert

Subjects
medicine.medical_specialty, Blood transfusion, medicine.drug_class, medicine.medical_treatment, Proton-pump inhibitor, Peptic Ulcer Hemorrhage, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Pharmacology (medical), 030212 general & internal medicine, Omeprazole, Hepatology, medicine.diagnostic_test, business.industry, Anti-ulcer Agent, Retrospective cohort study, Effective dose (pharmacology), 3. Good health, Endoscopy, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

SUMMARY High-dose omeprazole reduces the rate of recurrent bleeding after endoscopic treatment of peptic ulcer bleeding. However, the effectiveness of high-dose vs. standard-dose omeprazole in peptic ulcer bleeding has never been shown. Aim To compare the benefits of high-dose vs. standard-dose omeprazole in peptic ulcer bleeding. Methods We reviewed the medical files of patients admitted between 1997 and 2004 for high-risk peptic ulcer bleeding who had undergone successful endoscopic treatment. We distinguished 2 periods: before 2001, standarddose omeprazole (40 mg ⁄ day intravenously until alimentation was possible, then 40 mg ⁄ day orally for 1 week); after 2001, high-dose omeprazole (80 mg bolus injection, then 8 mg ⁄ h continuous infusion for 72 h, then 40 mg ⁄ day orally for 1 week). During both periods, patients subsequently received omeprazole, 20 mg ⁄ day, orally for 3 weeks. Results We enrolled 114 patients (period 1, n = 45, period 2, n = 69). Therapy with high-dose omeprazole significantly decreased the occurrence of poor outcome (27 vs. 12%, P = 0.04), rebleeding (24 vs. 7%, P = 0.01), mortality due to haemorrhagic shock (11 vs. 0%, P < 0.001) and need for surgery (9 vs. 1%, P = 0.05). Conclusions In this retrospective study, high-dose omeprazole reduced the occurrence of rebleeding, need for surgery and mortality due to hemorrhagic shock in patients with high-risk peptic ulcer bleeding, as compared with standard-dose omeprazole.

Published
2007
Full Text
View/download PDF

32. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study

Author

G.-P. Pageaux, Jean Charles Duclos-Vallée, F. Durand, L. D’Alteroche, Valérie Canva, H. Danjou, Audrey Coilly, Vincent Leroy, Danielle Botta-Fridlund, Claire Fougerou-Leurent, Pauline Houssel-Debry, Abou Diallo, Fabio Conti, Nassim Kamar, V. Di Martino, S. Radenne, Christophe Duvoux, A. Rohel, V. de Ledinghen, Jérôme Dumortier, Département d'hépatologie, Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, and CHU Toulouse [Toulouse]

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Hcv recurrence, Liver transplantation, Gastroenterology, 3. Good health, Internal medicine, medicine, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

33. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort

Author

Nassim Kamar, Jérôme Dumortier, Pascal Lebray, P. Perré, C. Silvain, Jean Charles Duclos-Vallée, Vincent Leroy, Audrey Coilly, Valérie Canva, V. Di Martino, Alain Renault, Pauline Houssel-Debry, G.-P. Pageaux, Danielle Botta-Fridlund, H. Danjou, C. Fougerou, Sylvie Radenne, Christophe Moreno, L. D’Alteroche, V. de Ledinghen, Camille Besch, Rodolphe Anty, Christophe Duvoux, A. Rohel, Service de Pharmacologie [Rennes], CHU Pontchaillou [Rennes], Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département d'hépatologie, Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Liver transplantation, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Immunology, Cohort, medicine, 030211 gastroenterology & hepatology, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

34. LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program

Author

Isabelle Rosa, V. de Ledinghen, Jean-Pierre Bronowicki, C. Silvain, Danielle Botta-Fridlund, Christophe Hézode, Yacia Bennai, Raoudha Akremi, M. Bourlière, Eric Nguyen-Khac, Pascal Lebray, I. Hubert-Fouchard, Dominique Larrey, Vincent Leroy, Hélène Fontaine, V. Di Martino, L. D’Alteroche, Dominique Guyader, Fabien Zoulim, Nathalie Boyer, Larysa Fedchuk, Fabrice Carrat, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Matière et Systèmes Complexes (MSC), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Amiens-Picardie, Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Nice Sophia Antipolis (... - 2019) (UNS), Matière et Systèmes Complexes (MSC (UMR_7057)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Service des maladies du foie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Epidémiologie, Systèmes dínformation et modélisation (ESIM), and CHU Saint-Antoine [APHP]

Subjects
medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, Ribavirin, [SDV]Life Sciences [q-bio], Compassionate Use, Interim analysis, Virology, 3. Good health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, Genotype, Medicine, 030211 gastroenterology & hepatology, In patient, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

35. P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic

Author

Stanislas Pol, Dominique Larrey, Hélène Fontaine, Valérie Canva, A. Tran, Christophe Hézode, Armando Abergel, Yoann Barthe, Laurent Alric, Thong Dao, Pierre Attali, J.-M. Pawlotsky, Damien Lucidarme, Didier Samuel, Patrice Cacoub, S. Metivier, Thierry Poynard, Paul Calès, V. de Ledinghen, Véronique Loustaud-Ratti, M. Bourlière, Isabelle Rosa, Fabrice Carrat, Véronique Grando-Lemaire, Fabien Zoulim, V. Di Martino, C. Dufour, Ghassan Riachi, Pierre-Henri Bernard, Jean-Pierre Bronowicki, Isabelle Portal, Lawrence Serfaty, T. Fontanges, Patrick Marcellin, J.-J. Raabe, Dominique Guyader, Xavier Causse, Jean-Pierre Zarski, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de recherche sur les Ions, les MAtériaux et la Photonique (CIMAP - UMR 6252), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Matériaux Avancés (IRMA), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Rouen Normandie (UNIROUEN), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille (APHM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut d'astrophysique spatiale (IAS), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National d’Études Spatiales [Paris] (CNES), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pitié-Salpêtrière [AP-HP], SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche en Cancérologie de Montpellier ( IRCM - U1194 Inserm - UM ), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Centre de recherche sur les Ions, les MAtériaux et la Photonique ( CIMAP - UMR 6252 ), Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Supérieure d'Ingénieurs de Caen ( ENSICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Assistance Publique - Hôpitaux de Marseille ( APHM ), Service d'hépatologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Institut d'astrophysique spatiale ( IAS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Service des maladies du foie, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Centre Hospitalier Universitaire de Rennes, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pitié-Salpêtrière [APHP], Interactions cellulaires et applications thérapeutiques ( ICAT ), Université d'Angers ( UA ) -CHU Angers-CRLCC Paul Papin-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), CIRAD, UPR AGIRs, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Epidémiologie, Systèmes dínformation et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Unité de Santé Publique, Assistance publique - Hôpitaux de Paris - AP-HP (FRANCE)-CHU Saint-Antoine [APHP], Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service d'hépatologie [CHU Saint-Antoine], Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou

Subjects
0303 health sciences, Pediatrics, medicine.medical_specialty, Hepatology, [ SDV ] Life Sciences [q-bio], business.industry, [SDV]Life Sciences [q-bio], Treatment experienced, 3. Good health, Telaprevir, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Boceprevir, Cohort, medicine, 030211 gastroenterology & hepatology, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

36. Sub optimal scheduling in a grid using genetic algorithms

Author

V. Di Martino and M. Mililotti

Subjects
Rate-monotonic scheduling, Computer Networks and Communications, Computer science, Distributed computing, Flow shop scheduling, Dynamic priority scheduling, Grid, computer.software_genre, Computer Graphics and Computer-Aided Design, Fair-share scheduling, Theoretical Computer Science, Scheduling (computing), Grid computing, Artificial Intelligence, Hardware and Architecture, Genetic algorithm, computer, Software
Abstract

The computing GRID infrastructure could benefit of techniques that can improve the over-all throughput of the system. It is possible that job submission will include different ontology in resource requests due to the generality of the GRID infrastructure. Such flexible resource request could offer the opportunity to optimize several parameters, from network load to job costs in relation to due time, more generally the quality of services. We present the result of the simulation of GRID jobs allocation. The search strategy for this input case does not converge to the optimal case inside the limited number of trial performed, in contrast with previous work on up to 24 jobs [Scheduling in a Grid Computing Environment using Genetic Algorithms, in: Proceedings of the International Parallel and Distributed Processing Symposium: IPDPS 2002 Workshops]. The benefits of the usage of the genetic algorithms to improve the quality of the scheduling is discussed. The simulation has been obtained using an environment GGAS suitable to study the scheduling of jobs in a distributed group of parallel machines. The modular structure of GGAS allows to expand its functionalities to include other first level schedule policy with respect to the FCFS that is considered. The result of this paper suggests the usage of local search strategy to improve the convergence when the number of jobs to be considered is as big as in real world operation.

Published
2004
Full Text
View/download PDF

37. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis

Author

Thierry Poynard, Jean François Cadranel, C. Goulenok, V. Di Martino, Dominique Thabut, B Bernard, and Pierre Opolon

Subjects
Cirrhosis, Hepatology, business.industry, Encephalopathy, Gastroenterology, Odds ratio, medicine.disease, Placebo, Confidence interval, law.invention, Randomized controlled trial, Flumazenil, law, Anesthesia, medicine, Pharmacology (medical), business, Hepatic encephalopathy, medicine.drug
Abstract

Background: Randomized controlled trials testing flumazenil in hepatic encephalopathy have shown conflicting results. Aim: To compare flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis. Methods: An overview of randomized controlled trials comparing flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis was performed. For each end-point, heterogeneity and treatment efficacy were assessed by Peto and Der Simonian methods. As most trials were crossover in nature, a sensitivity analysis was performed including the two treatment periods. Results: Six double-blind randomized controlled trials, including 641 patients (326 treated with flumazenil and 315 with placebo), were identified. The treatment duration ranged from 5 min to 3 days. Heterogeneity tests between control groups were not significant. The mean percentages of patients with clinical improvement (five trials) were 27% in treated groups and 3% in placebo groups. This difference was significant by both methods (Peto: odds ratio=6.15; 95% confidence interval, 4.0–9.5; P

Published
2002
Full Text
View/download PDF

38. Impact de l’infection à cytomégalovirus sur l’issue des patients cirrhotiques : une étude observationnelle

Author

Elisabeth Monnet, le groupe d’étude CiRCE, Morgan Faivre, and V. Di Martino

Subjects
Epidemiology, Public Health, Environmental and Occupational Health
Abstract

Etat de la question Chez les patients cirrhotiques, les determinants du carcinome hepatocellulaire (CHC) et de la mortalite de cause hepatique sont imparfaitement connus. Le cytomegalovirus (CMV), via ses proprietes pro-oncogeniques, pro-inflammatoires et immunosuppressives, pourrait favoriser le developpement du CHC et une inflammation systemique deletere. Notre objectif etait d’evaluer si l’infection a cytomegalovirus est associee au CHC et a la mortalite de cause hepatique chez les patients cirrhotiques. Materiel et methodes Parmi les 1178 patients inclus entre juin 2008 et decembre 2012 dans l’etude CIRCE, une etude cas–temoin multicentrique du Grand-Est de la France concue pour identifier les facteurs de risques de CHC chez les patients cirrhotiques indemnes de pathologie extrahepatique engageant le pronostic vital, 432 patients disposant d’un statut serologique CMV connu ou de serums a l’inclusion ont ete identifies, dont 159 cas avec CHC et 273 patients cirrhotiques sans CHC. Nous avons mesure les facteurs associes au CHC a l’inclusion ou a la survenue de CHC incidents chez les temoins, ainsi que les facteurs associes a la mortalite de toute cause et liee au foie dans toute la population d’etude. Resultats Durant un suivi median de 31 mois, 25 CHC sont survenus chez des temoins, et 209 deces (162 de cause hepatique) ont ete enregistres. Il y avait 247 (57,2 %) patients CMV-seropositifs. La seropositivite CMV n’etait pas associee a une frequence plus importante de CHC a l’inclusion ni au cours du suivi, mais parmi les patients CMV-seropositifs avec CHC, la proportion de tumeurs multinodulaires, infiltrantes ou metastatiques etait plus elevee (73,8 % versus 57,3 %, p = 0,029). Dans des regressions de Cox multivariees ajustees sur l’âge, le score MELD, la presence d’un CHC a l’inclusion et le diabete, la seropositivite CMV predisait la mortalite de toute cause (HR = 1,45 ; IC95 % : 1,08–1,94 ; p = 0,013) et de cause hepatique (HR = 1,56 ; IC95 % : 1,04–2,30 ; p = 0,031). Conclusion Les patients cirrhotiques CMV-seropositifs sont a risque de deceder d’une cause hepatique, en raison de CHC plus agressifs ou de complications hepatiques graves.

Published
2017
Full Text
View/download PDF

39. A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis

Author

Frédéric Oberti, V. Di Martino, L. Elkrief, Rodolphe Anty, Didier Lebrec, Thierry Thevenot, Richard Moreau, Nathalie Gault, Jean-Marc Perarnau, Marie-Angèle Robic, Isabelle Ollivier-Hourmand, L. D’Alteroche, Pierre-Emmanuel Rautou, Blandine Pasquet, Alexandre Louvet, Violaine Ozenne, C. Bureau, Sophie Hillaire, Marika Rudler, Faouzi Saliba, and P. Nahon

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, medicine.disease, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, Child-Pugh Class C, In patient, business, Norfloxacin, medicine.drug
Published
2017
Full Text
View/download PDF

40. Acute colitis: differential diagnosis using multidetector CT

Author

Lucine Vuitton, Laurianne Plastaras, Eric Delabrousse, V. di Martino, Stéphane Koch, and Nicolas Badet

Subjects
Adult, Male, medicine.medical_specialty, Colon, Infectious Colitis, Inflammatory bowel disease, Gastroenterology, Diagnosis, Differential, Young Adult, Ischemia, Internal medicine, Multidetector Computed Tomography, Odds Ratio, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Colitis, Acute colitis, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Reproducibility of Results, General Medicine, Odds ratio, Bacterial Infections, Middle Aged, medicine.disease, Abscess, medicine.anatomical_structure, Acute Disease, Etiology, Abdomen, Female, Lymph Nodes, Differential diagnosis, business
Abstract

To investigate the utility of multidetector CT (MDCT) in helping to establish the underlying cause of acute colitis.All patients who had acute colitis with a well-identified cause and underwent abdomen 64-MDCT were included in the study. MDCT images were retrospectively analysed in a blinded fashion and the CT findings were correlated with the eventual aetiological diagnosis.The study population included 105 patients. Acute colitis was related to inflammatory bowel disease in 43 cases. MDCT was used to identify six relevant signs of inflammatory colitis: the "comb" sign (p0.001), enlarged lymph nodes (p0.001), abscess (p = 0.026), fibro-fatty infiltration (p = 0.007), small bowel involvement (p0.001), and the absence of an "empty colon" sign (p = 0.045). Multivariate logistic regression analysis identified three independent signs of inflammatory colitis: the "comb" sign, small bowel involvement, and enlarged lymph nodes. Acute colitis was related to bacterial infection in 35 cases. Five signs were significantly associated with infectious colitis: continuous distribution (p = 0.020), an "empty colon" sign (p = 0.002), absence of fat stranding (p = 0.013), and absence of a "comb" sign (p = 0.010) and absence of enlarged lymph nodes (p = 0.035). Multivariate analysis identified three independent signs: the "empty colon" sign and absence of fat stranding and of a "comb" sign. The remaining causes were ischaemic colitis (n = 21) and drug-related colitis (n = 6). MDCT examination provided five relevant signs of ischaemic colitis: fat stranding (p = 0.002), discontinuous distribution (p0.001), and absence of enlarged lymph node (p0.001), a "comb" sign (p = 0.006) and small bowel involvement (p = 0.037).MDCT provides certain suggestive signs that may be helpful in distinguishing the underlying aetiological cause of acute colitis.

Published
2014

41. Thrombose portale par diffusion de cyanoacrylate au décours de l’obturation de varices gastriques hémorragiques

Author

Stéphane Koch, C. Amouroux, J.-P. Cervoni, Thierry Thevenot, Eric Delabrousse, and V. Di Martino

Subjects
business.industry, Gastroenterology, Portal vein, General Medicine, Gastric varices, medicine.disease, 03 medical and health sciences, Venous thrombosis, 0302 clinical medicine, 030220 oncology & carcinogenesis, medicine, 030211 gastroenterology & hepatology, Nuclear medicine, business
Published
2009
Full Text
View/download PDF

42. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

Author

François Bricaire, Thierry Poynard, F. Azria, Yves Benhamou, Frédéric Charlotte, V. Di Martino, Pierre Opolon, Michel Vidaud, Anne Coutellier, Marie Bochet, and Christine Katlama

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Hepatitis C virus, virus diseases, Immunosuppression, medicine.disease_cause, medicine.disease, Gastroenterology, digestive system diseases, Serology, Fibrosis, Internal medicine, Immunopathology, Immunology, medicine, Viral disease, Risk factor, Prospective cohort study, business
Abstract

The natural history of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients has never been studied according to the concept of liver fibrosis progression. The aim of this work was to assess the fibrosis progression rate in HIV-HCV coinfected patients and in patients infected by HCV only. A cohort of 122 HIV-HCV coinfected patients was compared with a control group of 122 HIV-negative HCV-infected patients. Groups were matched according to age, sex, daily alcohol consumption, age at HCV infection, and duration and route of HCV infection. The fibrosis progression rate was defined as the ratio between fibrosis stage (METAVIR scoring system) and the HCV duration. The prevalence of extensive liver fibrosis (METAVIR fibrosis scores 2, 3, and 4) and moderate or severe activity were higher in HIV-infected patients (60% and 54%, respectively) than in control patients (47% and 30%, respectively; P 50 g/d, P =.0002), age at HCV infection ( 50 g/d), CD4 count (

Published
1999
Full Text
View/download PDF

43. Cyamamezine-induced acute hepatitis after unique massive intake

Author

A. Cazier, V Pras, Philippe Bonnard, Bruno Devergie, M. Biour, V Di Martino, and Jean François Cadranel

Subjects
Adult, medicine.medical_specialty, Victimology, Suicide, Attempted, Cyamemazine, chemistry.chemical_compound, Phenothiazines, Internal medicine, Pharmacovigilance, medicine, Humans, Chlorpromazine, Hepatitis, Hepatology, Suicide attempt, business.industry, Gastroenterology, medicine.disease, Surgery, Liver, chemistry, Acute Disease, Toxicity, Etiology, Female, Chemical and Drug Induced Liver Injury, business, medicine.drug
Abstract

Hepatotoxicity of cyamamezine, a phenothiazine structurally related to chlorpromazine, has been rarely documented. We report here a case of acute symptomatic hepatitis following a unique massive intake of cyamamezine in a suicide attempt and discuss the mechanisms of such injury.

Published
1999
Full Text
View/download PDF

45. A case of isolated splenic infarction associated with a foramen ovale and an interatrial septal aneurysm

Author

V. Di Martino, A. Dobrin, Thierry Thevenot, N. Meneveau, B. Alby, N. Sailley, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
medicine.medical_specialty, Foramen secundum, MESH: Anticoagulants, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Aneurysm, MESH: Splenic Infarction, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, MESH: Heart Aneurysm, MESH: Humans, MESH: Middle Aged, business.industry, Vascular disease, MESH: Foramen Ovale, Gastroenterology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, General Medicine, Foramen ovale (skull), Primary interatrial foramen, medicine.disease, MESH: Heart Catheterization, MESH: Male, 3. Good health, Surgery, MESH: Abdominal Pain, medicine.anatomical_structure, Splenic infarction, MESH: Heart Atria, Splenic disease, business, Heart atrium
Abstract

National audience

Published
2008
Full Text
View/download PDF

46. Severe acute pancreatitis related to the use of adefovir in a liver transplant recipient

Author

A. Coaquette, G. Mantion, Franck Carbonnel, Natalie Simon, Jean-Philippe Miguet, Bernadette Kantelip, Audrey Weber, V. Di Martino, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Nutrition, hormones et cancer: épidémiologie et prévention (E3N), Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
MESH: Antiviral Agents, MESH: Liver Transplantation, medicine.medical_specialty, MESH: Adenine, Pancreatic disease, medicine.medical_treatment, MESH: Phosphonic Acids, Liver transplantation, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, MESH: Postoperative Complications, Internal medicine, medicine, Adefovir, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, MESH: Aged, MESH: Humans, MESH: Hepatitis B, Reverse-transcriptase inhibitor, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, General Medicine, Hepatitis B, medicine.disease, Virology, MESH: Male, MESH: Recurrence, 3. Good health, Transplantation, MESH: Pancreatitis, MESH: Acute Disease, Acute pancreatitis, Pancreatitis, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

International audience

Published
2008
Full Text
View/download PDF

47. P0821 : Are extended durations and/or ribavirin useful for genotype 1 (G1) cirrhotic patients who receive DAAs combination? A meta-analysis of randomized controlled trials (RCTS)

Author

J.-P. Cervoni, C. Richou, V. Di Martino, Delphine Weil, Claire Vanlemmens, and Thierry Thevenot

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Surgery, law.invention, chemistry.chemical_compound, chemistry, Randomized controlled trial, law, Meta-analysis, Internal medicine, Genotype, medicine, business
Published
2015
Full Text
View/download PDF

48. P0205 : Management of gastric varices: A french national survey

Author

C. Bureau, J.-P. Cervoni, Paul Castellani, V. Di Martino, N. Fares, Thierry Thevenot, Dominique Thabut, Thong Dao, Arnaud Pauwels, Frédéric Oberti, Nicolas Carbonell, Aurélie Plessier, Delphine Weil, and Marika Rudler

Subjects
medicine.medical_specialty, Hepatology, business.industry, General surgery, medicine, Gastric varices, medicine.disease, business
Published
2015
Full Text
View/download PDF

49. P0142 : Mortality risk factors in cirrhotic patients in Intensive Care Unit: A monocentric retrospective study at Besançon’s University Hospital from 2002 to 2014

Author

Gilles Capellier, J.-P. Cervoni, Gaël Piton, Claire Chaignat, C. Patry, and V. Di Martino

Subjects
medicine.medical_specialty, Hepatology, business.industry, law, Emergency medicine, medicine, Retrospective cohort study, business, University hospital, Intensive care unit, law.invention
Published
2015
Full Text
View/download PDF

50. P0132 : External validation of the CLIF-SOFA in cirrhotic patients admitted to intensive care units (ICUS): A meta-analysis

Author

Evangelos Cholongitas, Bertrand Sauneuf, J. Fichet, Constantine J. Karvellas, V. Di Martino, René Robert, Eric Levesque, Thierry Thevenot, Gilles Capellier, H.-C. Pan, Arnaud Galbois, Rodrigo Cavallazzi, Mark J. W. McPhail, Delphine Weil, Eleni Theocharidou, and Gaël Piton

Subjects
medicine.medical_specialty, Hepatology, business.industry, Clif sofa, Intensive care, Meta-analysis, Emergency medicine, External validation, medicine, business, Intensive care medicine
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results